Clinical trials: Androgen Deprivation Therapy
Prostate Cancer
Androgen Deprivation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens.
- Trial name
- NCT00110162
- Testing
- antiandrogen therapy, releasing hormone agonist therapy, orchiectomy
- Where
- 20 sites in Australia, New Zealand
- Volunteers
- 2,000 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Prostate Cancer, Supportive Care
Behavioral Exercise Training to Reduce Cardiovascular Disease Risk
To test the preliminary effectiveness of a home-based exercise training (ET) intervention to improve exercise capacity (VO2 peak \& 6-minute walk distance [6MWD]) among prostate cancer (PC) patients compared to controls receiving…
- Trial name
- EXTRA-PC (NCT06237179)
- Testing
- Exercise Training Intervention, Healthy Living Education
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Virginia Commonwealth University
Prostate Cancer
Exemestane With or Without Bicalutamide in Treating Patients With Stage IV Prostate Cancer
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using exemestane plus bicalutamide may fight prostate cancer by reducing the production of androgens.
- Trial name
- NCT00031889
- Testing
- Exemestane, Exemestane+bicalutamide
- Where
- 12 sites in Switzerland
- Volunteers
- 5 people
- Sponsor
- Swiss Cancer Institute
Prostate Cancer
Using Walk With Ease Walking Program With Men 65 and Older Being Treated for Prostate Cancer
This study is testing a walking program called Walk with Ease by the Arthritis Foundation with men undergoing treatment for prostate cancer.
- Trial name
- NCT02139774
- Testing
- Walk with Ease
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Prostate Cancer
The Effect of Endurance Training on Body Composition and Insulin Sensitivity in Prostate Cancer Patients Receiving Androgen Deprivation Therapy
The purpose of the present study is to investigate if endurance training can be used as a therapeutic action against the adverse metabolic disturbances and unfavourable changes in body composition that accompany the androgen…
- Trial name
- NCT01676480
- Testing
- Endurance training
- Where
- Denmark
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Inge Holm
Prostate Cancer
A Survivorship Care Plan and Embedded Navigation Tool
This is a parallel group, multisite prospective clinical study. The purpose of this study is to evaluate whether ASCENT enables patients to adhere to the survivorship guidelines and improves coordination of care to address…
- Trial name
- ASCENT (NCT03424837)
- Testing
- ASCENT
- Where
- 6 sites in United States
- Volunteers
- 77 people
- Sponsor
- Duke University
Prostate Cancer
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
The purpose of this study is to compare the effects, good and/or bad of two treatment methods on subjects and their cancer. Proton beam radiation therapy is one of the treatments for men with prostate cancer who have localized…
- Trial name
- NCT01492972
- Testing
- Radiation, Androgen Suppression Therapy
- Where
- 4 sites in United States
- Volunteers
- 192 people
- Sponsor
- Proton Collaborative Group
COVID-19, SARS-CoV2
Anti-Androgen Treatment for COVID-19
This study is intended to explore the possible protective role of anti-androgens in SARS-CoV-2 infection
- Conditions
- COVID-19, SARS-CoV2, Androgenetic Alopecia, Prostate Cancer
- Trial name
- NCT04446429
- Testing
- Proxalutamide, Standard of Care
- Where
- Brazil
- Volunteers
- 268 people
- Sponsor
- Applied Biology, Inc.
Castration-Sensitive Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer
This phase II trial studies how well antiandrogen therapy, abiraterone acetate, and prednisone with or without neutron radiation therapy work in treating patients with prostate cancer.
- Conditions
- Castration-Sensitive Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma
- Trial name
- NCT03649841
- Testing
- Antiandrogen Therapy, Abiraterone Acetate, Prednisone
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Washington
Prostate Cancer
Best Systemic Therapy or Best Systemic Therapy (BST) Plus Definitive Treatment (Radiation or Surgery)
The goal of this clinical research study is to learn if treatment with standard systemic therapy (androgen deprivation therapy or bilateral orchiectomy) in combination with surgery or radiation therapy is more effective at…
- Trial name
- NCT01751438
- Testing
- Best Systemic Therapy (BST), Best Systemic Therapy (BST) + Surgery or Radiation Therapy, Questionnaires
- Where
- 4 sites in United States, Canada
- Volunteers
- 180 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Leveraging Technology to Achieve Equity for Men With Prostate Cancer on Androgen Deprivation Therapy
This clinical trial studies a digital platform, the supportive therapy in androgen deprivation (STAND-T), in achieving equity for men undergoing treatment with androgen deprivation therapy for prostate cancer.
- Trial name
- NCT05324098
- Testing
- STAND-T platform, Survey Administration, Text Messages
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- University of California, San Francisco
Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy
The study is being conducted to evaluate the efficacy and safety of SHR3680 plus androgen deprivation therapy (ADT) vs. placebo plus ADT in patients with high-risk localized or locally advanced prostate cancer using pathologic…
- Trial name
- NCT05009290
- Testing
- SHR3680
- Where
- China
- Volunteers
- 391 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Prostate Cancer
Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer
The purpose of this study is to determine whether DCVAC/PCa added onto hormone therapy can improve PSA progression times for patients with Metastatic Prostate Cancer.
- Trial name
- NCT02107391
- Testing
- Dendritic Cells DCVAC/PCa, Leuprolide acetate, Goserelin Acetate
- Where
- 9 sites in Czechia
- Volunteers
- 63 people
- Sponsor
- SOTIO a.s.
Metastatic Hormone-sensitive Prostate Cancer, Darolutamide (DARO) in Combination With Androgen-deprivation Therapy (ADT) and Docetaxel (DOC)
Evaluation of the Efficacy of Darolutamide Triplet Therapy in Patients With Metastatic Hormone-sensitive Prostate Cancer
The purpose of this study is to investigate the clinical efficacy and safety of darolutamide combined with androgen deprivation therapy (ADT) and different dose-intensity docetaxel chemotherapy in the treatment of patients with…
- Trial name
- NCT07031258
- Testing
- Dose of docetaxel
- Volunteers
- 50 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Reccurent/Metastatic Solid Tumor Disease, Prostate Cancer (Post Prostatectomy)
Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery.
Study Overview This research compares two types of post-operative salvage radiotherapy (SRT) for men with prostate cancer who have had surgery but show signs of recurrence (detectable PSA).
- Conditions
- Reccurent/Metastatic Solid Tumor Disease, Prostate Cancer (Post Prostatectomy), Prostate Cancer, Prostatic Neoplasms
- Trial name
- HYP-OP-RT (NCT07483658)
- Testing
- Standard Fractionation Post-Operative Salvage Radiotherapy (25 fractions), Hypofractionated Post-Operative Salvage Radiotherapy (20 fractions), Androgen Deprivation Therapy (ADT)
- Where
- 4 sites in Canada
- Volunteers
- 434 people
- Sponsor
- CHU de Quebec-Universite Laval
Prostate Cancer
Xbox Kinect Training in Men With Prostate Cancer
The purpose of this study is to investigate the effect of 12 weeks systematically training using the Xbox Kinect system. Outcome measures are made on physical function, quality of life, fatigue and metabolic parameters.
- Trial name
- NCT01762241
- Testing
- Home based training using the Xbox Kinect system
- Where
- 3 sites in Denmark
- Volunteers
- 46 people
- Sponsor
- Hospitalsenheden Vest
Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel
Androgen Deprivation Therapy Combined With Docetaxel for High Risk Prostate Cancer
This randomized, controlled, single center clinical trial aims to evaluate the efficacy and safety of Androgen Deprivation Therapy Combined with Docetaxel for High Risk Prostate Cancer with a six-month treatment cycle.
- Trial name
- NCT04869371
- Testing
- Docetaxel injection, Triptorelin Pamoate for Injectable Suspension, Prednisone Acetate Tablets
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Hongqian Guo
Prostate Carcinoma
Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer
This phase II trial compares the effect of oxybutynin versus placebo for reducing hot flashes in men receiving androgen deprivation (hormone) therapy for the treatment of prostate cancer .
- Trial name
- NCT04600336
- Testing
- Oxybutynin Chloride, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 103 sites in United States
- Volunteers
- 88 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer Adenocarcinoma in Situ
A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer
This research is being done to see if an investigational prostate cancer vaccine, called GVAX, can safely be given together with a single intravenous injection of a drug called cyclophosphamide to men that will undergo surgery to…
- Trial name
- NCT01696877
- Testing
- degarelix acetate, Cyclophosphamide, GVAX
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer, mHSPC
Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer
The goal of this phase 3 clinical trial is to determine the clinical effectiveness and cost effectiveness of using lower doses of Androgen Receptor Pathway Inhibitors (ARPI) to treat patients with prostate cancer that has spread…
- Conditions
- Prostate Cancer, mHSPC, mCRPC
- Trial name
- ENHANCE (NCT07751133)
- Testing
- Abiraterone, Apalutamide, Enzalutamide or Darolutamide (ARPI therapy) (per standard of care) therapy
- Where
- 2 sites in United Kingdom
- Volunteers
- 1,500 people
- Sponsor
- University College, London